DE69819696D1 - Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien - Google Patents

Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien

Info

Publication number
DE69819696D1
DE69819696D1 DE69819696T DE69819696T DE69819696D1 DE 69819696 D1 DE69819696 D1 DE 69819696D1 DE 69819696 T DE69819696 T DE 69819696T DE 69819696 T DE69819696 T DE 69819696T DE 69819696 D1 DE69819696 D1 DE 69819696D1
Authority
DE
Germany
Prior art keywords
reducing agents
beta amyloid
amyloid reducing
detecting beta
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819696T
Other languages
English (en)
Other versions
DE69819696T2 (de
Inventor
Barbara Cordell
Slanec Higgins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of DE69819696D1 publication Critical patent/DE69819696D1/de
Application granted granted Critical
Publication of DE69819696T2 publication Critical patent/DE69819696T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69819696T 1997-03-21 1998-03-19 Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien Expired - Lifetime DE69819696T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/821,876 US6221670B1 (en) 1997-03-21 1997-03-21 Methods to identify β-amyloid reducing agents
US821876 1997-03-21
PCT/US1998/005363 WO1998043094A1 (en) 1997-03-21 1998-03-19 METHODS TO IDENTIFY β-AMYLOID REDUCING AGENTS

Publications (2)

Publication Number Publication Date
DE69819696D1 true DE69819696D1 (de) 2003-12-18
DE69819696T2 DE69819696T2 (de) 2004-09-16

Family

ID=25234504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819696T Expired - Lifetime DE69819696T2 (de) 1997-03-21 1998-03-19 Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien

Country Status (9)

Country Link
US (1) US6221670B1 (de)
EP (1) EP0970379B1 (de)
JP (1) JP2002508834A (de)
AT (1) ATE254287T1 (de)
AU (1) AU6567198A (de)
CA (1) CA2284261A1 (de)
DE (1) DE69819696T2 (de)
ES (1) ES2212277T3 (de)
WO (1) WO1998043094A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7119085B2 (en) 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
GB0010565D0 (en) * 2000-05-02 2000-06-21 Medical Res Council Assay for acetylcholinesterase inhibitors
DE60116313T2 (de) * 2000-06-30 2006-08-31 Elan Pharmaceuticals, Inc., San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US6846641B2 (en) * 2002-04-23 2005-01-25 Agy Therapeutics, Inc. In vitro ischemia model
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
BRPI0513959A (pt) * 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
US20130046093A1 (en) 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
US9638548B2 (en) 2012-05-07 2017-05-02 Infineon Technologies Ag Output switching systems and methods for magnetic field sensors
US10102992B2 (en) 2014-02-25 2018-10-16 Infineon Technologies Ag Switching apparatus, switching system and switching method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production

Also Published As

Publication number Publication date
CA2284261A1 (en) 1998-10-01
WO1998043094A1 (en) 1998-10-01
ATE254287T1 (de) 2003-11-15
EP0970379A1 (de) 2000-01-12
US6221670B1 (en) 2001-04-24
EP0970379B1 (de) 2003-11-12
AU6567198A (en) 1998-10-20
JP2002508834A (ja) 2002-03-19
ES2212277T3 (es) 2004-07-16
DE69819696T2 (de) 2004-09-16

Similar Documents

Publication Publication Date Title
DE69819696D1 (de) Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien
DE69510342T2 (de) Verfahren zum nachweis der permeabilität eines gegenstandes für sauerstoff
DE59601159D1 (de) Verfahren zum gegenseitigen ausrichten von körpern und lagemesssonde hierfür
DE69128344T2 (de) Vorrichtung und verfahren für elektrochemische messungen
DE69115360T2 (de) Verfahren und Gerät zur Pflege der Aktivität einer Enzymelektrode
DE69513248T2 (de) Zusammensetzung, Verfahren und System zum Nachweis von Leukocyten, Esterasen oder Proteasen in einer Testprobe
DE69431677D1 (de) Verfahren und Methode für geometrische Messung
DE69328783D1 (de) Verfahren für direkte spektrophotometrische messungen in unverändertem blut
DE69535692D1 (de) Verfahren und Vorrichtung zur automatisierten Prüfung von Photomasken
DE69331797T2 (de) Verfahren und Gerät zur Überwachung der Rauschzahl eines optischen Verstärkers
DE69827066D1 (de) Verfahren und Vorrichtung zum Kompensieren von Mehrkanalechos
EP0277237A4 (de) Verfahren, sowie sonde zum nachweis von bakterien in mustern.
DE59510661D1 (de) Verfahren zum qualitativen und/oder quantitativen Nachweis einer zu bestimmenden Substanz
DE69504949T2 (de) Verwendung eines Antagonisten der Substanz P zur Behandlung von Hautrötungen neurogen Ursprungs
DE3575787D1 (de) Verfahren und vorrichtung zur zerstoerungsfreien pruefung ferromagnetischer koerper mittels magnetisierung.
DE283382T1 (de) Verfahren zur funktionspruefung eines automaten und einrichtung zu dessen ausfuehrung.
DE69320457D1 (de) Verfahren und anordnung für bioaffinitätsassays
DE69028104T2 (de) Verfahren zur proteinbindung-enzym-komplementationstests
DE3680381D1 (de) Reagenz und verfahren zum messen der amylaseaktivitaet.
DE69408427D1 (de) Dimensionsmessverfahren und Eichmass für dieses Verfahren
DE69322801D1 (de) Enzym für Spaltung und Verfahren zu seiner Herstellung
DE3584844D1 (de) Verfahren und anordnung zur sekundaerfeldbohrlochmessung der dielektrizitaetskonstante.
DE69032309T2 (de) Verfahren und Vorrichtung zum Identifizieren der Wiedergabe-Art
BR8805933A (pt) Metodo para testar enzimas
ATA6594A (de) Verfahren zum aeroben mikrobiologischen dekontaminieren von gasen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition